Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tempest Therapeutics, Inc. (TPST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.81-0.25 (-2.26%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.06
Open10.86
Bid10.40 x 800
Ask11.50 x 900
Day's Range10.42 - 10.86
52 Week Range9.35 - 41.55
Volume5,572
Avg. Volume26,417
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.00
  • GlobeNewswire

    Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

    Combination based on both strong mechanistic rationale and preclinical data SOUTH SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both tumor-targeted and immune-mediated mechanisms, today announced the first patient has been dosed with TPST-1495 in combination with pembrolizumab in the Phase 1a/1b open-label, dose and schedule optimization study of TPST-14

  • GlobeNewswire

    Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

    Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported in vitro and in vivo preclinical data demonstrating the potent dual mechanistic activity of TPST-1495, an orally-available small molecule designed to block th

  • GlobeNewswire

    Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights

    First patients dosed in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (“HCC”) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La RocheExclusive rights to novel oncology target in-licensed from the lab of Russell Vance, Ph.D., at the University of California at Berkeley (“U.C. Berkeley”) SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially fi

Advertisement
Advertisement